Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out if standard chemotherapy given with
idarubicin and Cytarabine (ara-C) can help to control AML.
Objectives:
To determine the complete response (CR) rate, event-free survival (EFS) and overall survival
(OS) of patients with newly diagnosed acute myeloid leukemia (AML) receiving standard
combination chemotherapy with Idarubicin and cytarabine.